[{"orgOrder":0,"company":"Infinant Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"INF108","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Infinant Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Infinant Health \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Infinant Health \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Infinant Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma Live Expo
                          Not Confirmed
                          Pharma Live Expo
                          Not Confirmed

                          Details : Infinant Health's patented drug candidate is a Bifidobacterium longum subspecies infantis strain, INF108, being developed for the prevention of necrotizing enterocolitis in pre-term infants.

                          Product Name : INF108

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          February 04, 2024

                          Lead Product(s) : INF108

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank